GR1802

Phase 3Small molecule

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

GR1802 is one of 33 small molecule programs targeting Chronic Rhinosinusitis With Nasal Polyps. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis With Nasal PolypsUnknown status

Seasonal Allergic RhinitisRecruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Unknown status

Seasonal Allergic RhinitisPhase 3

Recruiting

Competition

Competitive Landscape

25 competitors in Seasonal Allergic Rhinitis

#DrugCompanyPhaseTrials

Zyrtec

KKenvue Brands

Approved

7 2

Allegra

CChattem

Approved

7 3

Clarinex

OOrganon and Co

Approved

7 4

Flovent

PParatek Pharmaceuticals Inc

Approved

7 5

Claritin

PPerrigo Company

Approved

4 6

Asmanex Hfa

PPerrigo Company

Approved

3 7

Singulair

OOrganon and Co

Approved

3 8

Xyzal

CChattem

Approved

2 9

Tylenol

KKenvue Brands

Approved

—10

Proair HFA

GGlaxo Dba Glaxosmithkline

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Seasonal Allergic Rhinitis

NCT07199257

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis3 trials

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07154342·150 enrolled

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06315426·240 enrolled

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

Not yet recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07199257·144 enrolled

Chronic Rhinosinusitis With Nasal Polyps3 trials

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT05873803·70 enrolled

The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Unknown status·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06015243·70 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps

Completed·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT06516302·228 enrolled

Asthma1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Unknown status·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06642961·150 enrolled

Atopic Dermatitis1 trial

Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Unknown status·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT06216392·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for GR1802. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GR1802 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GR1802. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genrix (Shanghai) Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

GR1802

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Seasonal Allergic Rhinitis3 trials

Chronic Rhinosinusitis With Nasal Polyps3 trials

Asthma1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News